Cargando…
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Anti-programmed cell death 1 (PD1) immunotherapies are among the most effective anti-cancer immunotherapies available; however, a large number of patients present with or develop resistance to them. Unfortunately, very little is known regarding the mechanisms of resistance to such therapies. A recen...
Autores principales: | O’Donnell, Jake S., Smyth, Mark J., Teng, Michele W. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080691/ https://www.ncbi.nlm.nih.gov/pubmed/27782862 http://dx.doi.org/10.1186/s13073-016-0365-1 |
Ejemplares similares
-
PD1 functions by inhibiting CD28-mediated co-stimulation
por: O'Donnell, Jake S, et al.
Publicado: (2017) -
Acquired Resistance to Immune Checkpoint Blockade Therapies
por: Zhao, Xianda, et al.
Publicado: (2020) -
Checkpoint Inhibitors in Checkmating Rare Cancers
por: Srinivas, Sujay, et al.
Publicado: (2021) -
CD24Fc: an emerging COVID-19 therapy
por: Eckhardt, Christina M, et al.
Publicado: (2022) -
Comment on Chen et al. Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin. Biomolecules 2021, 11, 1373
por: Stransky, Nicolai, et al.
Publicado: (2022)